Samsung Biologics Completes Rockville Facility Acquisition

Samsung Biologics has completed its acquisition of a biologics manufacturing facility in Rockville from GSK. The site includes two cGMP plants with a combined 60,000-liter capacity, supporting both clinical and commercial production.

Samsung Biologics will continue producing products for GSK at the Rockville site while expanding operations to support additional contract manufacturing needs. The company plans to invest in capacity expansion and technology upgrades, and more than 500 employees will transition to Samsung Biologics. The acquisition marks Samsung Biologics’s first manufacturing presence in the United States.